Mark E. Pearson Net Worth

The estimated Net Worth of Mark E. Pearson is at least $8.6 millió dollars as of 17 October 2018. Mark Pearson owns over 170,000 units of Soligenix Inc stock worth over $8,600,000 and over the last 6 years Mark sold SNGX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Pearson SNGX stock SEC Form 4 insiders trading

Mark has made over 1 trades of the Soligenix Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Mark bought 170,000 units of SNGX stock worth $197,200 on 17 October 2018.

The largest trade Mark's ever made was buying 170,000 units of Soligenix Inc stock on 17 October 2018 worth over $197,200. On average, Mark trades about 34,000 units every 0 days since 2018. As of 17 October 2018 Mark still owns at least 2,500,000 units of Soligenix Inc stock.

You can see the complete history of Mark Pearson stock trades at the bottom of the page.

What's Mark Pearson's mailing address?

Mark's mailing address filed with the SEC is 29 EMMONS DRIVE, SUITE B-10, , PRINCETON, NJ, 08540.

Insiders trading at Soligenix Inc

Over the last 15 years, insiders at Soligenix Inc have traded over $502,220 worth of Soligenix Inc stock and bought 775,279 units worth $1,096,136 . The most active insiders traders include Randal Jintrexon Corp Kirk, Jerome B Zeldis és Spacavazza Paolo Leadiant B.... On average, Soligenix Inc executives and independent directors trade stock every 115 days with the average trade being worth of $91,349. The most recent stock trade was executed by Richard Straube on 18 May 2022, trading 8,000 units of SNGX stock currently worth $4,000.

What does Soligenix Inc do?

soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.

Complete history of Mark Pearson stock trades at Soligenix Inc

Soligenix Inc executives and stock owners

Soligenix Inc executives and other stock owners filed with the SEC include:

• Dr. Christopher J. Schaber Ph.D.,
  Chairman, CEO & Pres
• Christopher Schaber,
  Chairman of the Board, President, Chief Executive Officer
• Dr. Oreola Donini Ph.D.,
  Sr. VP & Chief Scientific Officer
• Oreola Donini,
  Senior Vice President, Chief Scientific Officer
• Dr. Richard C. Straube M.D., MSc.,
  Sr. VP & Chief Medical Officer
• Jonathan L. Guarino CPA, CGMA,
  Sr. VP, CFO & Corp. Sec.
• Richard Straube,
  Senior Vice President and Chief Medical Officer
• Jonathan Guarino,
  Chief Financial Officer, Senior Vice President, Corporate Secretary
• Jerome Zeldis,
  Independent Director
• Robert Rubin,
  Independent Director
• Diane Parks,
  Independent Director
• Gregg Lapointe,
  Independent Director
• Richard L. Dunning,
  Exec. Officer
• Marco Maria Brughera,
  Director
• Keith L Brownlie,
  Director
• Karen R Krumeich,
  SVP and CFO
• Joseph Michael Warusz,
  VP of Finance/Acting CFO
• Randal Jintrexon Corp Kirk,
  
• Spacavazza Paolo Leadiant B...,
  
• Mark E. Pearson,
  Director
• Kevin Horgan,
  Senior VP; Chief Med Officer
• Virgil Thompson,
  Director
• Tamar D Howson,
  Director
• Management Llc Berman Ross ...,
  
• Robert N Brey,
  Chief Science Officer & Sr VP
• Paolo Cavazza,
  10% owner
• Evan Myrianthopoulos,
  CFO and Senior Vice Presient
• Brian L Hamilton,
  Chief Medical Officer & Sr VP
• Christopher P. Schnittker,
  VP-Admin., Controller
• Tau Finanziaria Spasigma Ta...,
  
• Claudio Cavazza,
  10% owner
• Timothy R. Cote,